D.A. Davidson & CO. Grows Stock Position in Twist Bioscience Co. (NASDAQ:TWST)

D.A. Davidson & CO. grew its position in shares of Twist Bioscience Co. (NASDAQ:TWST) by 3.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 19,618 shares of the company’s stock after purchasing an additional 664 shares during the period. D.A. Davidson & CO.’s holdings in Twist Bioscience were worth $886,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Signaturefd LLC increased its stake in Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after buying an additional 306 shares during the period. EdgeRock Capital LLC purchased a new stake in shares of Twist Bioscience during the second quarter worth about $43,000. Blue Trust Inc. lifted its stake in shares of Twist Bioscience by 2,912.8% in the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after acquiring an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new position in Twist Bioscience in the second quarter valued at about $61,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after purchasing an additional 381 shares in the last quarter.

Insider Activity at Twist Bioscience

In other news, insider Dennis Cho sold 1,507 shares of Twist Bioscience stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $48.00, for a total transaction of $72,336.00. Following the sale, the insider now owns 91,163 shares of the company’s stock, valued at approximately $4,375,824. The trade was a 1.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Paula Green sold 3,310 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $43.21, for a total value of $143,025.10. Following the completion of the transaction, the senior vice president now directly owns 84,585 shares of the company’s stock, valued at $3,654,917.85. This trade represents a 3.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 98,118 shares of company stock worth $4,391,151 in the last 90 days. 3.92% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. JPMorgan Chase & Co. increased their target price on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research note on Monday, August 5th. Barclays decreased their price objective on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, November 19th. Evercore ISI upped their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. TD Cowen reiterated a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a research note on Tuesday, November 26th. Finally, Leerink Partners upped their price objective on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $51.00.

Twist Bioscience Stock Up 1.8 %

Shares of TWST stock opened at $49.18 on Monday. The business has a 50 day moving average of $43.84 and a two-hundred day moving average of $46.23. The company has a market cap of $2.92 billion, a P/E ratio of -13.66 and a beta of 1.78. Twist Bioscience Co. has a 52 week low of $23.25 and a 52 week high of $60.90.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.